Clinical Data ECO 2026: SURMOUNT-MAINTAIN proves tirzepatide sustains weight loss long term Pharmaceutical TechnologyAt ECO 2026, data from the SURMOUNT-MAINTAIN trial evaluating the use of Eli Lilly's Zepbound (tirzepatide) in sustaining weight loss was presented.Metabolic & GLP-1Read full story pharminent May 15, 2026 (Last updated: May 21, 2026) Pharmaceutical Technology At ECO 2026, data from the SURMOUNT-MAINTAIN trial evaluating the use of Eli Lilly’s Zepbound (tirzepatide) in sustaining weight loss was presented. Metabolic & GLP-1 Read full story Post navigation Previous: Trial miss doesn’t dent Biogen’s faith in Alzheimer’s drugNext: Kyowa Kirin secures FDA approval for Crysvita dosing update Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026